Kyverna Therapeutics, Inc.
KYTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kyverna Therapeutics, Inc. focuses on Biotechnology services and products. Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. With a market capitalization of $452.9M, it sits in small-cap territory. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Market Cap
$452.9M
Beta
1.88
P/E (TTM)
—
P/E (Fwd)
-2.52
EPS (TTM)
$-3.28
EPS (Fwd)
$-2.95
ROE
-74.6%
ROA
-39.6%
Cash
$236.4M
Total Debt
$33.8M
Free CF
-$93.8M
52W Change
91.0%
Annual Financials
Cash vs Debt
With $236.4M in cash and $33.8M in debt, KYTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$93.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -74.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $5.7M (2021) to $0 (2025), a 100% decline worth watching.
Kyverna Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kyverna Therapeutics, Inc. and its sector.